Лечение симптомов нижних мочевых путей у пациентов с доброкачественной гиперплазией предстательной железы: современные международные стандарты

1. Athanasopoulos A. The Role of Antimuscarinics in the Management of Men With Symptoms of Overactive Bladder Associated With Concomitant Bladder Outlet Obstruction: An Update. Eur Urol 2011. http://www.doi:10.1016/j.eururo.2011.03.054
2. Hutchison A, Farmer R, Verhamme K et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007; 51: 207–16.
3. Brown CT, Yap T, Cromwell DA et al. Self-management for men with lower urinary tract symptoms – a randomised controlled trial. BMJ 2007; 334 (7583): 25.
4. McConnell JD. For the MTOPS Research Group. The long term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med 2003; 349: 2385–96.
5. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158 (2): 481–9.
6. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate 1990; 3 (Suppl.): 1–7.
7. Flanigan RC, Reda DJ, Wasson JH et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic BPH: a Department of Veterans Affairs cooperative study. J Urol 1998; 160 (1): 12–6.
8. Gravas S (chair), Bachmann A, Descazeaud A et al. Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). http://www.uroweb.org/gls/pdf/Non-Neurogenic%20Male%20LUTS_(2705).pdf
9. Djavan B, Chapple C, Milani S et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64 (6): 1081–8.
10. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5a-reductase inhibitors for the enlarged prostate. Clin Ther 2007; 29 (1): 17–25.
11. Roehrborn CG, Boyle P, Nickel JC et al. ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60 (3): 434–41.
12. Sairam K, Kulinskaya E, Mc-Nicholas TA et al. Sildenafil influences LUTS. Brit J Urol Int 2002; 90 (7): 836–9.
13. Uckert S, Oelke М. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Brit J Clin Pharmacol 2011; 72 (2): 197–204.
14. Roehrborn CG, McVary KT, Elion-Mboussa A et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180 (4): 1228–34.
15. Porst H, McVary KT, Montorsi F et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and sign and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56 (4): 727–35.
16. Kaplan Steven A. Medical Therapy for Benign Prostatic Hyperplasia: New Terminology, New Concepts, Better Choices. Rev Urol 2006; 8 (1): 14–22.
17. Witte LP, Mulder WM, De la Rosette JJ et al. Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 2009; 19 (1): 13–9.
18. Roehrborn CG, Siami P, Barkin J et al. CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57 (1): 123–31.
19. Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 2006; 296 (19): 2319–28.
20. Mamoulakis C, Trompetter M, De la Rosette J. Bipolar transurethral resection of the prostate: the ‘golden standard’ reclaims its leading position. Curr Opin Urol 2009; 19 (1): 26–32.
21. Gilling PJ, Aho TF, Frampton CF et al. Holmium laser enucleation of the prostate: results at 6 years. Eur Urol 2008; 53 (4): 744–9.
22. Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 2008; 53 (1): 160–6.
23. Mattiasson A, Abrams P, Van Kerrebroeck P et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002; 89 (9): 855–62.
24. Yu X, Elliott SP, Wilt TJ et al. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol 2008; 180 (1): 241–5.

П.И.Раснер, Д.Ю.Пушкарь

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России